Previous Close | 0.3180 |
Open | 0.3330 |
Bid | 0.3134 x 200 |
Ask | 0.3158 x 10600 |
Day's Range | 0.3021 - 0.3550 |
52 Week Range | 0.0510 - 1.2200 |
Volume | |
Avg. Volume | 67,743,385 |
Market Cap | 92.21M |
Beta (5Y Monthly) | 1.38 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7700 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.60 |
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-secretory agents to treat canine diarrhea SAN FRANCISCO, ...
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failure Proof-of-concept studies of crofelemer ...
Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called "chemo mouth") in Q3 2024 Company to feature "Make Cancer Less Shitty" patient advocacy program at ONS Congress SAN FRANCISCO, CA ...